Enjoy complimentary customisation on priority with our Enterprise License!
The tardive dyskinesia (TD) treatment market size is estimated to grow by USD 632.45 million at a CAGR of 4.73% between 2023 and 2028.
To early detection of growing cases of mental disorders, including schizophrenia, depression, and others, the tardive dyskinesia treatment is beneficial. In addition, TD is prompted by a long intake of medicines that block dopamine receptors in the brain to treat psychological disorders like schizophrenia. Furthermore, the prolonged intake of medications to treat mental illness can lead to TD, which in turn will fuel the demand for tardive dyskinesia treatment, thereby driving the growth of the global tardive dyskinesia treatment market during the forecast period.
Technavio has segmented the market into End-user, Product, and Geography
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2018-2022, besides analyzing the current market scenario.
To learn more about this report, Request Free Sample
The market share growth by the hospital pharmacy segment will be significant during the forecast period. The regulatory systems for pharmacies favor the dominance of hospital pharmacies in the global tardive dyskinesia treatment market. Hospitals are significant healthcare locations where tardive dyskinesia treatments are consulted and carried out, and patients receive medical attention, which in turn fuels the demand for hospital pharmacies.
Get a glance at the market contribution of various segments Download PDF Sample
The hospital pharmacy segment was valued at USD 1.05 billion in 2018. The growing cases of mental disorders across the world are further fueling the global tardive dyskinesia treatment market. Hence, the growing cases of mental disorders and easy governance of hospital pharmacies are driving the demand for TD drugs from hospital pharmacies, which in turn will fuel the growth of the global tardive dyskinesia (TD) treatment market during the forecast period.
The Austedo and Ingrezza are used to treat the movement disorder chorea, which is associated with Huntington's Disease, and to treat tardive dyskinesia. These products are being used to block vesicular monoamine transporter type 2 (VMAT2) and reduce dopamine uptake in the brain. Although some reduction in symptoms may be noticed within a week or two, it can take up to 32 weeks (for TD) to have an effect. Thus, the high prevalence of tardive dyskinesia is anticipated to fuel the growth of the Austedo and Ingrezza segment, which in turn will drive the growth of the global tardive dyskinesia treatment market during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers will shape the market during the forecast period. The tardive dyskinesia treatment market in North America is expected to witness significant growth due to increasing healthcare expenditure and the presence of well-established healthcare infrastructure.
Furthermore, anyone who has been treated for schizophrenia, bipolar disorder, schizoaffective disorder, anxiety, or depression and has taken or is taking antipsychotics is at high risk for developing TD. Hence, the growing cases of such bipolar disorders will lead to a higher prevalence of TD, which in turn will fuel the growth of the tardive dyskinesia treatment market in North America during the forecast period.
The outbreak of COVID-19 in 2020 had a negative impact on the tardive dyskinesia treatment market in the North American region. However, in 2021, the initiation of large-scale vaccination drives?lifted the lockdown and travel restrictions, which led to the resumption of supply chain activities. Furthermore, the growing healthcare expenditure and rising awareness regarding TD are expected to fuel the growth of the regional tardive dyskinesia treatment market during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Abbott Laboratories: The company offers tardive dyskinesia treatment such as Aripiprazole or abilify drug.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key trends, and challenges.
Initiatives to spread awareness regarding treatment of tardive dyskinesia is the primary trend shaping market growth. Many governments are promoting the awareness of TD by launching awareness week programs. All 50 states in the US, Washington, DC, and various mental health advocacy organizations have recognized the first week of May (1-7) 2023 as TD Awareness Week. This awareness week addressed approximately 600,000 Americans living with involuntary movement disorder.
Furthermore, Teva Pharmaceutical Industries Ltd. launched the It's Not OK - It's TD national television advertising campaign to raise awareness of TD and Austedo (Deutetrabenazine) tablets in May 2021. Hence, such initiatives to spread awareness regarding treatment of tardive dyskinesia are expected to drive the growth of the market during the forecast period.
Side effects related to tardive dyskinesia drugs is a challenge that affects market growth. The effective and FDA-approved drugs for the treatment of tardive dyskinesia are Austedo and Ingrezza. However, these drugs have certain side effects that can have negative impacts on human health. Agitation or restlessness, sleep problems, and swellings in the nose and throat are some of the side effects of Austedo observed in people who received the treatment for TD
Furthermore, boxed warning, long QT syndrome, neuroleptic malignant syndrome (NMS), and allergic reactions are some serious side effects that have been reported who received Austedo for the treatment of TD. Hence, the side effects related to tardive dyskinesia drugs are expected to negatively affect the growth of the global tardive dyskinesia treatment market during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Tardive Dyskinesia Treatment Market Customer Landscape
The tardive dyskinesia treatment market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.
|
Tardive Dyskinesia Treatment Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
147 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 4.73% |
|
Market Growth 2024-2028 |
USD 632.45 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
4.22 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 38% |
|
Key countries |
US, Germany, UK, France, and China |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Abbott Laboratories, Actiza Pharmaceutical Pvt. Ltd., Alembic Pharmaceuticals Ltd., Aspire Pharma Ltd., Centaur Pharmaceuticals Pvt. Ltd., Cipla Ltd., Hetero Labs Ltd., Lannett Co. Inc., Luye Pharma Group Ltd., Neurocrine Biosciences Inc., Novartis AG, Psicofarma S. A. de C. V, Ryon pharma, Sawai Group Holdings Co. Ltd., Slate Run Pharmaceuticals LLC, Solco Healthcare, SOM Innovation Biotech S.A., SteriMax Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
Let us help you make report more suited to your requirements.
Get the report (PDF) sent to your email within minutes.
